In 2004, an early study showed that the p38 mitogen-activated protein kinase (MAPK) inhibitor SB203580 could suppress DSS-induced experimental colitis via inhibiting NOD2 effector RIPK2 in the NOD2/RIPK2/NF-κB signaling pathway [165]. Here, NOD2 is linked to colitis.